Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Anti-apoptotic B cell lymphoma 2 (BCL2) family members (BCL2, MCL1, BCLxL, BCLW, and BFL1) are key players in the regulation of intrinsic apoptosis. Dysregulation of these proteins not only impairs normal development, but also contributes to tumor progression and resistance to various anti-cancer therapies. Therefore, cells maintain strict control over the expression of anti-apoptotic BCL2 family members using multiple mechanisms. Over the past two decades, the importance of post-transcriptional regulation of mRNA in controlling gene expression and its impact on normal homeostasis and disease have begun to be appreciated. In this review, we discuss the RNA binding proteins (RBPs) and microRNAs (miRNAs) that mediate post-transcriptional regulation of the anti-apoptotic BCL2 family members. We describe their roles and impact on alternative splicing, mRNA turnover, and mRNA subcellular localization. We also point out the importance of future studies in characterizing the crosstalk between RBPs and miRNAs in regulating anti-apoptotic BCL2 family member expression and ultimately apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
MicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049
Towards a molecular understanding of microRNA-mediated gene silencing
Jonas, S., & Izaurralde, E. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3965 · Cited by 1,872 · cited 1×
“For more details about the molecular mechanisms of miRNA-mediated gene silencing, see ref [94].”
BackgroundSpliceosome Structure and Function
Will, C. L., & Luhrmann, R. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003707 · Cited by 1,829 · cited 1×
“Pre-mRNA splicing is catalyzed by the spliceosomal small nuclear ribonuclear proteins (snRNPs) which bind to the 5′ splice site, 3′ splice site, and branch site in a pre-mRNA (reviewed in [28]).”
BackgroundContext-dependent control of alternative splicing by RNA-binding proteins
Fu, X.-D., & Ares, M. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3778 · Cited by 1,044 · cited 1×
“Pre-mRNA also contains cis-acting elements including exonic and intronic splicing enhancers or silencers associated with multiple regulatory RBP proteins that either enhance or repress spliceosomes assembled at the splice sites (reviewed in [29,30]).”
BackgroundAutophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039 · cited 1×
“Tightly regulated apoptosis plays important roles in multiple aspects of both normal physiology, such as development [2] and immune responses [3,4], and disease biology such as neurodegenerative diseases [5,6], cardiovascular diseases [7,8], carcinogenesis [9,10], and treatment responses to certain drugs [9,11].”
BackgroundFrom basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752 · cited 3×
“Due to their importance in normal physiology and disease biology especially cancers, regulatory mechanisms of the anti-apoptotic BCL2 family members are being widely studied with several reviews focused on their transcriptional controls [18,19] and post-translational modifications [23–25].”
BackgroundRegulation of cytoplasmic mRNA decay
Schoenberg, D. R., & Maquat, L. E. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3160 · Cited by 656 · cited 2×
“These cis-acting elements are commonly located in the 3′ untranslated region (UTR) of a RNA [73].”
BackgroundSignal-dependent regulation of splicing via phosphorylation of Sam68
Matter, N., Herrlich, P., & König, H. (2002) · Nature · doi:10.1038/nature01153 · Cited by 458 · cited 1×
“STAR proteins have been shown to be modified by multiple signaling pathways including phosphorylation [56], methylation [57], acetylation [58], and SUMOylation [59].”
BackgroundTwo mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma
Li, X., Liu, Y., Granberg, K. J., Wang, Q., Moore, L. M., Ji, P., Gumin, J., Sulman, E. P., Calin, G. A., Haapasalo, H., et al. (2015) · Oncogene · doi:10.1038/onc.2014.98 · Cited by 99 · cited 1×
“Later reports have shown that miR-491 induces apoptosis by targeting BCLxL in colorectal cancer [139], glioblastoma [140], and ovarian cancer [126].”
BackgroundEhrmann, I., Dalgliesh, C., Liu, Y., Danilenko, M., Crosier, M., Overman, L., Arthur, H. M., Lindsay, S., Clowry, G. J., Venables, J. P., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003474 · Cited by 82 · cited 1×
“Other STAR proteins such as T-STAR [63] and ASD-2 (alternative splicing defective protein 2) [64] have also been identified as splicing regulators, but more studies are necessary to pursue their roles in regulating BCLx alternative splicing.”
Background
Cited by
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Basu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Viel, T., Toricelli, M., Pereira, A. R., Souza Abrao, G., Malerba, H., Maia, J., & Buck, H. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.286952 · Cited by 102
“When activated, the proapoptotic oligomers Bax and Bak are coupled to the membrane of the mitochondria (Cui and Placzek, 2018).”
Interplay between protein acetylation and ubiquitination controls MCL1 protein stability
Shimizu, K., Gi, M., Suzuki, S., North, B. J., Watahiki, A., Fukumoto, S., Asara, J. M., Tokunaga, F., Wei, W., & Inuzuka, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109988 · Cited by 62
“…growth factors and cytokines induce MCL1 gene expression (Thomas et al., 2010), multiple microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) control the stability of MCL1 mRNA (Cui and Placzek, 2018; Senichkin et al., 2020), and mTORC1 promotes MCL1 protein translation (Mills et al., 2008).”
Zhang, Q., Liu, X.-M., Hu, Q., Liu, Z.-R., Liu, Z.-Y., Zhang, H.-G., Huang, Y.-L., Chen, Q.-H., Wang, W.-X., & Zhang, X.-K. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03027-6 · Cited by 52
Metadata
- Authors
- Cui, J., & Placzek, W.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-01-20
- Volume
- 19
- Issue
- 1
- Pages
- 308
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2793567331
- Cited by
- 134
- References
- 14
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.